meso-N-[(3-endo)-8-{2-[4-([1,3]thiazolo[4,5-b]pyrazin-2-yloxy)phenoxy]ethyl}-8-azabicyclo[3.2.1]oct-3-yl]acetamide | 1190925-68-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: meso-N-[(3-endo)-8-{2-[4-([1,3]thiazolo[4,5-b]pyrazin-2-yloxy)phenoxy]ethyl}-8-azabicyclo[3.2.1]oct-3-yl]acetamide
• CAS: 1190925-68-8
• 化学式: C₂₂H₂₅N₅O₃S
• 分子量: 439.538
• InChiKey: KBRWUZVCRHEXPY-BJWYYQGGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.39
• 重原子数：
  31.0
• 可旋转键数：
  7.0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  89.47
• 氢给体数：
  1.0
• 氢受体数：
  8.0

文献信息

• Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase
  申请人：Bacani Genesis M.

  公开号：US20090258854A1

  公开（公告）日：2009-10-15

  Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amine compounds are described, which are useful as LTA4 hydrolase (LTA4H) modulators. Such compounds may be used in pharmaceutical compositions and methods for modulation of LTA4H and for the treatment of disease states, disorders, and conditions mediated by LTA4 hydrolase activity.

  描述了噻唑吡啶-2-氧基苯基和噻唑吡嗪-2-氧基苯基胺化合物，这些化合物可作为LTA4水解酶（LTA4H）调节剂。这些化合物可以用于制备药物组合物，用于调节LTA4H并治疗由LTA4水解酶活性介导的疾病状态、疾病和症状。
• THIAZOLOPYRIDIN-2-YLOXY-PHENYL AND THIAZOLOPYRAZIN-2-YLOXY-PHENYL AMINES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE
  申请人：Janssen Pharmaceutica, N.V.

  公开号：EP2268646B1

  公开（公告）日：2013-10-02
• US7939527B2
  申请人：——

  公开号：US7939527B2

  公开（公告）日：2011-05-10
• [EN] THIAZOLOPYRIDIN-2-YLOXY-PHENYL AND THIAZOLOPYRAZIN-2-YLOXY-PHENYL AMINES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE<br/>[FR] AMINES DE THIAZOLOPYRIDIN-2-YLOXY-PHENYL ET DE THIAZOLOPYRAZIN-2-YLOXY-PHENYL EN TANT QUE MODULATEURS DE LEUKOTRIENE A4 HYDROLASE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2009126806A2

  公开（公告）日：2009-10-15

  Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amine compounds are described, which are useful as LTA4 hydrolase (LTA4H) modulators. Such compounds may be used in pharmaceutical compositions and methods for modulation of LTA4H and for the treatment of disease states, disorders, and conditions mediated by LTA4 hydrolase activity.